Charles River Laboratories International (NYSE:CRL) Stock Price Up 8% – What’s Next?

Charles River Laboratories International, Inc. (NYSE:CRL) was up 8% on Tuesday . The company traded as high as $241.50 and last traded at $242.2370. 120,726 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 911,609 shares. The stock had previously closed at $224.30.

Wall Street Analyst Weigh In

Several brokerages have commented on CRL. Morgan Stanley increased their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st. Barclays upped their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $220.75.

Charles River Laboratories International Stock Performance

The business’s fifty day moving average is $200.29 and its 200-day moving average is $187.42. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market cap of $11.39 billion, a PE ratio of -62.88, a P/E/G ratio of 2.52 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after purchasing an additional 47,432 shares in the last quarter. Invesco Ltd. grew its position in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares in the last quarter. State Street Corp increased its stake in Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Finally, Geode Capital Management LLC raised its position in Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after purchasing an additional 9,756 shares during the period. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.